TY - JOUR T1 - Response to: ‘Let's not fool ourselves. In RA, the ACR/EULAR remission criteria are not perfect!’ by Baker <em>et al</em> JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e13 LP - e13 DO - 10.1136/annrheumdis-2016-210799 VL - 76 IS - 6 AU - Maarten Boers Y1 - 2017/06/01 UR - http://ard.bmj.com/content/76/6/e13.abstract N2 - Baker et al1 raise many interesting points on the validity and use of the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) remission criteria that I would like to reflect on.But first of all I would like to reiterate my main point, one which I think we agree on:In all clinical trials where remission is one of the outcomes, it should be defined according to the ACR/EULAR criteria.Baker et al list several concerns on these criteria that are well taken, and some that are generic to the way we measure disease activity today.Indeed, the ACR/EULAR criteria were developed with the express aim to define remission, more specifically ‘to develop a definition of remission that is stringent but achievable and could be applied uniformly as an outcome measure in clinical trials’. Although the committee was … ER -